Wednesday, July 31, 2013

A Timeless Lesson in Portfolio Management

In June I celebrated Father's Day by putting together a portfolio of 10 stocks that remind me of my dad. It was just a way to say thanks to him for getting me interested in investing at such a young age. I also vowed to keep track of this portfolio, as I'm confident that through the years it will be a market-beater, making Mr. Market green with envy. Granted, it's only been a bit more than a month since its inception, but let's see where things stand today as we start winding down earnings season.

The score 
Out of all 10 stocks, only one is actually down on an absolute basis, and that's Google  (NASDAQ: GOOG  ) (-0.1%). Six of the 10 are beating the market. The four losing to the market are Dick's Sporting Goods (-2.9%), Apple (NASDAQ: AAPL  )  (-1.3%), Google (-3.5%), and UPS (-2.9%). And on a simple, non-time-adjusted basis, if you invested $1,000 in each of the 10 picks, you'd have $10,556.68 today versus the $10,338.42 you'd have if you'd plunked it all down in the S&P 500. Not a bad start.

You got your winnahs
Ford  (NYSE: F  ) has been one of the stronger performers, and that's for good reason. Things are looking up as quarterly revenue rose 15%, which resulted in bottom-line earnings growth of 19%,and management is seeing improving conditions in foreign markets like Europe and China. Ford is gaining market share, too. In fact its share jumped from 16.1% in June 2012 to 16.7% in June 2013. General Motors (NYSE: GM  ) , on the other hand, lost market share, falling from 19.3% to 18.9% over the same time period.

And you got your losahs
They can't all be winners all of the time, though, and while I'm a big proponent of owning a basket of Amazon, Google, and Apple, two of those three are losing to the market right now. Google's most recent quarter wasn't a bad one by any stretch, but it did in fact miss estimates on both sales and earnings. One of the concerns investors have today is the downward trend in cost-per-click (the amount of money Google makes when people click on its ads). Cost-per-click was down 6% over the same quarter last year as the move to mobile continues to grow. However, on the upside, the total number of paid clicks continues to trend upward with growth of 23% over the same time period.

Apple has fallen from the market's good graces; the stock is down more than 36% from highs over $700 in the past year. We know Mr. Market doesn't like uncertainty, and as it stands, there are a lot of questions Apple must answer in regard to new products. Never mind the fact that its balance sheet is the envy of many countries, with almost $147 billion in cash and equivalents. And never mind that the company sold 31.2 million iPhones in the quarter, representing 20% growth over the same quarter last year. The 14% drop in iPad sales over the same time period only brings more questions, and until Tim Cook can provide some meaningful answers, Apple may be stuck in neutral for a while.

Making it all make sense
So what does this all mean? Not much, really. I don't measure my investing success based on such short time frames. But it's also good to know what's going on in your portfolio. I don't subscribe to the notion that you should only check your portfolio once or twice a year. If you do that, in my opinion, you're asking for trouble. At the very least, I think it makes sense to check your portfolio at least four times a year, if not more. Earnings season comes around every quarter, so it's easy to remember.

Don't get me wrong, I'm not suggesting you take action every quarter; far from it. As a matter of fact, unless there's a crisis of epic proportions, you should just let things be. But earnings season can also offer up some genuine opportunities to add to some of your favorite positions thanks to Mr. Market's short-term nature, so keep that in mind. Everybody has his or her own way of doing things, and the idea is for you to figure out yours. This is mine; it's simply how I invest.

This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

Click here to follow Jason on Twitter.

3 FTSE 100 Shares Going Ex-Dividend Next Week

LONDON -- If you want to be eligible for a dividend payment, or if you're watching for possible share-price falls, keeping up with ex-dividend dates can prove beneficial. So long as you hold the shares up to and including that day, you'll get your money.

We have a number of companies from the FTSE 100 reaching their crucial dates next week. Here are three that will go ex-dividend next Wednesday, June 26.

Compass Group (LSE: CPG  )
Catering and support services firm Compass Group announced an interim dividend of 8 pence per share along with first-half results on May 15, and that represented an 11% rise on the previous year. Revenue rose by 4.1% to £8.8 billion, with underlying pre-tax profit up 8.1% to £611 million and earnings per share up 11% to 24.5 pence.

If the second-half dividend is lifted by a similar 11%, we should be looking at a full-year payment of 23.6 pence per share for a yield of 2.8% on the current share price of 845 pence. The forward yield would have been more than 3%, had the share price not risen by 30% over the past 12 months.

NEXT (LSE: NXT  )
The same day is final ex-dividend day for high-street clothing chain NEXT. After reporting a 3.1% rise in revenue for the year to January 2013, a 9% rise in underlying pre-tax profit, and a 16.6% boost to underlying EPS, Next declared a final dividend of 74 pence per share.

That takes the full-year payment up 16.7 pence to 105 pence per share and follows Next's policy of lifting its dividend in line with EPS. With the share price currently at 4,605 pence, the total payment represents a yield of 2.3%.

Tate & Lyle (LSE: TATE  )
It's a final dividend for Tate & Lyle, too, with a payment of 18.8 pence per share to come. The year to March 31 brought in a 6% rise in sales on a constant-currency basis to £3.3 billion, with adjusted pre-tax profit up 4% to £329 million.

Adjusted EPS rose 5% to 57 pence, allowing the firm to lift its full-year dividend by 5.2% to 26.2 pence per share -- a yield of 3.2% on today's share price of 819 pence. The Tate & Lyle dividend has been raised for three consecutive years now, and forecasts suggest more of the same for this year and next -- but a steadily rising share price has lowered the yield.

Dividends like these can add nicely to your investment returns -- they can be spent or reinvested, according to your needs. Whether you're investing for income or growth, good old cash is always welcome. And that's why I recommend the brand-new Fool report "The Motley Fool's Top Income Share For 2013," in which our top analysts identify a share they believe will provide handsome dividend income for years to come. But it will only be available for a limited period, so click here to get your copy today.

Top 10 Biotech Companies To Buy Right Now

In this video, David Williamson reviews Johnson & Johnson's latest earnings report. The over-the-counter and nutritional business both grew, as did the pharma division, with a blood thinner holding its own and a new diabetes drug that looks promising. Medical devices saw a 10% uptick, but that was considered a disappointment in light of recent acquisitions.

David says he's neutral on the stock, but he also notes its 2.9% dividend and thinks it could prove to be a safe long-term investment. Check out the video for more details.

Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know whether J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.�

Top 10 Biotech Companies To Buy Right Now: Organovo Holdings Inc (ONVO.PK)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The C ompany has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an aut! om! ated device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Top 10 Biotech Companies To Buy Right Now: Telik Inc (TELK.PH)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tole rated. In June 2011, the Company initiated a Phase II clini! c! al trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transf usions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolera bility of the combinations was similar to that expected! of e! ac! h drug ! alone.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60 404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multipl e, standard preclinical models of cancer. TLK6059! 6, a pote! nt! VGFR kin! ase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

5 Best Casino Stocks To Buy Right Now: Fuse Science Inc (DROP)

Fuse Science, Inc. ( Fuse Science), incorporated on September 21, 1988, is a consumer products holding company. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can be consumed orally, applied topically or delivered otherwise sublingually or transdermally, thereby bypassing the gastrointestinal tract and entering the blood stream directly. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. In December 2012, the Company launched its initial DROP products, PowerFuse, an energy formulation in a concentrated drop and ElectroFuse, an electrolyte formula in a concentrated drop, online, with the expansion into targeted retail distribution channels.

The Company is developing formulations and devices, which are compatible with alternative delivery systems for energy, medicines, vitamins and minerals, among other bioactives. These alternative systems include, but are not limited to, sublingual, transdermal and buccal drug delivery methods. use Science has developed and continues to advance, in conjunction with its scientific team, sublingual and transdermal delivery systems for bioactives that can effectively encapsulate and charge varying molecules in order to produce product formulations which can be consumed orally, applied topically or otherwise delivered sublingually or transdermally, thereby bypassing the gastrointestinal tract and entering the blood stream directly. The delivery technology is consists of encapsulation vesicles and ion exchange permeation enhancers. This technology utilizes a gradient across the mucosa membrane to help deliver the bioactive more efficiently through the mucosa.

The Company�� products consist of EnerJel, PowerFuse and ElectroFuse. Ene! rJel is a topical product leveraging some of its technology, which is designed to address muscle fatigue and soreness, before, during and after physical activity. The product contains a natural anti-inflammatory and energy source which is directly applied to the problem area. PowerFuse contains natural ingredients, causes no sugar crash with zero calories and less than half the caffeine of an eight ounce cup of premium coffee. It is available in a great tasting Berry Blast Flavor. ElectroFuse contains natural ingredients, causes no sugar crash with zero calories, is easily portable and is available in a great tasting Salty-Sweet flavor.

Top 10 Biotech Companies To Buy Right Now: Quintiles Transnational Holdings Inc (Q)

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company operates in two segments: Product Development and Integrated Healthcare Services. The Company�� Product Development segment operates as a contract research organization (CRO) focused primarily on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company�� Integrated Healthcare Services segment is a global commercial pharmaceutical sales and service organizations and Integrated Healthcare Services provides a range of services, including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as healthcare business services for the healthcare sector, such as outcome-based and payer and provider services. In August 2012, it acquired Expression Analysis, Inc.

Product Development

Product Development provides services and that allow biopharmaceutical companies to outsource the clinical development process from first in man trials to post-launch monitoring. The Company�� service offering provides the support and functional necessary at each stage of development, as well as the systems and analytical capabilities. Product Development consists of clinical solutions and services and consulting. Clinical solutions and services provides services necessary to develop biopharmaceutical products, including project management and clinical monitoring functions for conducting multi-site trials (generally Phase II-IV) (core clinical) and clinical trial support services that improve clinical trial decision making and include global laboratories, data management, biostatistical, safety and pharmacovigilance, and early clinical development trials, and strategic planning and design services that improve decisions and performance. Consulting provides strategy and management consulting services based on life science and advanced analytics, as well as regulatory and comp! liance consulting services.

The Company competes with Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc. (inVentive), INC Research and PRA International.

Integrated Healthcare Services

Integrated Healthcare Services provides the healthcare industry with both geographic presence and commercial capabilities. The Company�� commercialization services are designed to accelerate the commercial of biopharmaceutical and other health-related products. Service offerings include commercial services (sales representatives, strategy, marketing communications and other areas related to commercialization), outcome research (drug therapy analysis, real-world research and evidence-based medicine, including research studies to prove a drug�� value) and payer and provider services comparative and cost-effectiveness research capabilities, clinical management analytics, decision support services, medication adherence and health outcome optimization services, and Web-based systems for measuring quality improvement.

The Company competes with inVentiv, PDI, Inc., Publicis Selling Solutions, United Drug plc, EPS Corporation and CMIC HOLDINGS Co., Ltd.

Top 10 Biotech Companies To Buy Right Now: Cubist Pharmaceuticals Inc.(CBST)

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous, antibiotic with activity against gram-positive organisms, including methicillin-resistant staphylococcus aureus. Its clinical development product pipeline consists of CXA-201, which is in the phase III clinical trial for patients with complicated urinary tract infections; and in phase II clinical trial for patients with complicated abdominal infections. The company is also developing CXA-201 for the treatment of hospital acquired pneumonia. In addition, its product under development comprises CB-183,315, an oral, bactericidal lipopeptide with in vitro bactericidal activity against C. difficile, for the treatment of clostridium difficile-associated diarrhea (CDAD). Further , the company?s pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. Additionally, it promotes MERREM I.V. (meropenem for injection), a carbapenem class intravenous antibiotic, in the United States under a commercial services agreement with AstraZeneca Pharmaceuticals, LP; and DIFICID as the treatment for CDAD in adults under the co-promotion agreement with Optimer Pharmaceuticals, Inc. The company also has collaborations with Forma Therapeutics, Inc. to discover and develop antibacterial compounds; an agreement with the Broad Institute to transform natural products discovery; a collaboration with Hydra Biosciences, Inc., to develop ion channel drugs; and a collaboration agreement with Alnylam Pharmaceuticals, Inc., for the development and commercialization of Alnylam's RNAi therapeutics as a therapy for the treatment of respiratory syncytial virus. The company was founded in 1992 and is headquartered in Lexington, Mas sachusetts.

Advisors' Opinion:
  • [By Melly Alazraki]

    Cubist Pharmaceuticals (CBST)rounds out the top five best biotech performers in the S&P 1500, according to Capital IQ, with a 16.3% return year-to-date. The smaller company ($1.48 billion market cap) relies on its anti-bacterial drugCubicin, used in hospitals for difficult-to-treat infections, including MRSA, formost of its revenue.

    While the company'spipelineconsists of otherantibiotic potentialsto address this unmet need area of severe infections, its revenue source is in jeopardy: Generic drugmaker Teva Phamaceutical (TEVA) istrying to enter the market.

  • [By Dug]

    Cubist Pharmaceuticals(CBST) is a major player in anti-infectives, which prevent and treat diseases, specifically those caused by drug-resistant pathogens. For example, Cubist's major product, Cubicin, is used to treat complicated skin and skin structure infections as well as bacterimia.

    The company has two anti-biotics that are in stage two of FDA approval. Since 2008, Cubist has grown sales and earnings per share 29% and 24% annually, on average. Its stock delivered annualized gains of 8.9% over that period. Recent deterioration of growth has led to a sell-off in Cubist, disconcerting investors.

    Its stock is down 4% over the past three months. Fourth-quarter adjusted earnings decreased 28% year-over-year, but did beat the consensus estimate by 38%. The top-line, down 3%, missed consensus by 1.1%. The operating margin strengthened during the quarter, from 28% to 29%, indicating pricing strength. Jefferies is optimistic about the outcome of a patent litigation lawsuit, which has a trial date in April, and considers the small-cap undervalued, at just 13-times forward earnings, a 39% peer discount. But, it considers reliance on Cubicin a concentrated risk.

    Bullish Scenario: Jefferies expects Varian to rise 39% to $31.

    Bearish Scenario: ThinkEquity foresees a drop of 10% to $20.

Top 10 Biotech Companies To Buy Right Now: Transition Therapeutics Inc.(TTHI)

Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada. Its lead products include ELND005 (AZD-103), a Phase II clinical trial product for the treatment of Alzheimer?s disease; TT-301 and TT-302, which are Phase I clinical trial products, for the treatment of rheumatoid arthritis, Alzheimer?s disease, traumatic brain injury, and intracerebral hemorrhage; and TT401/402, a preclinical stage product to treat diabetes. The company also has an emerging pipeline of preclinical and clinical drug candidates for the treatment of anti-inflammatory and metabolic indications. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005 (AZD-103); and a licensing and collaboration agreement with Eli Lilly and Company to develop and commercialize gastrin based therapies, and the preclinical compound TT401/402. The company was formerly known as Transition T herapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. on December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.

Advisors' Opinion:
  • [By Fitz Gerald]

    Biomedical stocks are some of the best performers in the sector, and this is true of Transition Therapeutics. This stock recently saw a net profit margin of more than thirty five percent, and the company is a quality choice.

Top 10 Biotech Companies To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:
  • [By Glenn]

    A relatively new company, Alnylam Pharmaceuticals was founded in 2002, and their shares have shown steady growth since before January 2005. In early January 2012, the shares were worth about $30 and although there were some dips to less than $20 in October/November of this year, they ended up around $25 at the end of December. Alnylam develops RNAi therapies for respiratory diseases and Huntington's, among others and has a broad spectrum of products in its pipeline. This startup also has agreements with number of large companies including Novartis, Biogen an d Roche.

Top 10 Biotech Companies To Buy Right Now: Organovo Holdings Inc (ONVO)

Organovo Holdings, Inc. (Organovo), formerly Real Estate Restoration & Rental, Inc., incorporated in 2007, is a development-stage company. The Company has developed and is commercializing a platform technology for the generation of three-dimensional (3D) human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. On December 28, 2011, Real Estate Restoration and Rental, Inc.�� (RERR) entered into an Agreement and Plan of Merger, pursuant to which RERR merged with its, wholly owned subsidiary, Organovo (Merger Sub). On February 8, 2012, the Company merged with and into Organovo Acquisition Corp. (Acquisition Corp.), a wholly owned subsidiary of Organovo, with the Company surviving the merger as a wholly owned subsidiary of Organovo Holdings (the Merger). As a result of the Merger, Organovo acquired the business of Organovo, Inc.

The Company has collaborative research agreements with Pfizer, Inc. (Pfizer) and United Therapeutic Corporation (Unither). As of March 31, 2012, it has five federal grants, including Small Business Innovation Research grants and developed the NovoGen MMX Bioprinter (its first-generation 3D bioprinter). The Company is engaged in the development of specific 3D human tissues to aid Pfizer in discovery of therapies in two areas of interest. In addition, in October 2011, it entered into a research agreement with Unither to establish and conduct a research program to discover treatments for pulmonary hypertension using its NovoGen MMX Bioprinter technology. Additionally, under the research agreement with Unither, the Company granted Unither an option to acquire from the Company a worldwide, royalty-bearing license in certain intellectual property created under the research agreement solely for use in the treatment or prevention of pulmonary hypertension and all other lung diseases.

The Company�� NovoGen MMX Bioprinter is an automate! d device that enables the fabrication of three-dimensional (3D) living tissues comprised of mammalian cells. A custom graphic user interface (GUI) facilitates the 3D design and execution of scripts that direct precision movement of the dispensing heads to deposit cellular building blocks (bio-ink) or supporting hydrogel. The Company is using a third party manufacturer, Invetech Pty., of Melbourne, Australia, to manufacture its NovoGen MMX Bioprinter. Its bioprinting technology and surrounding intellectual property and commercial rights serve as a platform for product generation across multiple markets that employ cell- and tissue-based products and services.

The Company competes with Organogenesis, Advanced BioHealing, Tengion, Genzyme, HumaCyte and Cytograft Tissue Engineering.

Top 10 Biotech Companies To Buy Right Now: NeoStem Inc (NBS)

NeoStem, Inc., incorporated on September 18, 1980, operates in cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and consists of a separate therapeutic technology platform in addition to pharmaceuticals, biologics and medical devices. The Company�� business model includes the development of novel cell therapy products, as well as operating a contract development and manufacturing organization (CDMO) providing services to others in the regenerative medicine industry. Progenitor Cell Therapy, LLC, the Company�� wholly owned subsidiary (PCT), is a CDMO in the cellular therapy industry. PCT has provided pre-clinical and clinical current Good Manufacturing Practice (cGMP) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing.

PCT has two cGMP, cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. The Company�� wholly-owned subsidiary, Amorcyte, LLC (Amorcyte) is developing its own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents its clinically advanced therapeutic product candidate and enrollment for its Phase II PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (AMI) patients.

Through the Company�� subsidiary, Athelos Corporation (Athelos), the Company is collaborating w! ith Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. The Company�� pre-clinical assets include its Very Small Embryonic Like (VSEL) Technology platform. The Company has basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States.

Top 10 Biotech Companies To Buy Right Now: Celsion Corporation(CLSN)

Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company is developing its lead product, ThermoDox that is in Phase III clinical trial for primary liver cancer; and in phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a license agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market. The company also has a license agreement with Duke University under which it received exclusive rights to commercialize and use Duke's thermo-liposome technology. In addition, Celsion Corporation has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat a range of cancers. The company was founded in 1982 and is based in Columbia, M aryland.

Advisors' Opinion:
  • [By Putnam]

    This is another play on clinical trial progress as a catalyst for higher share prices. This micro-cap stock uses heat-sensitive nano-particles to precisely place cancer-treatment drugs within specific tumors. A number of approaches are currently being tested. The first approach uses its ThermoDox technology in conjunction with radio frequency (RF) ablation for primary liver cancer. ThermoDox is being evaluated under a special protocol assessment with the FDA in a pivotal 600-patient Phase III trial. Results from this study are expected to be released in the next few months.

    Celsion shares weakened in the first quarter, as the company has sold new stock on a pair of occasions to keep the balance sheet healthy. Further equity offerings appear likely, but with positive feedback from the FDA, shares could pop nicely higher before that happens.

Tuesday, July 30, 2013

Daniel Kahneman: Keeping Score May Be More Dangerous Than You Think

Dr. Daniel Kahneman, winner of the 2002 Nobel Prize in economics joins us to discuss his book, Thinking, Fast and Slow.

In this video segment, Daniel answers a question from the audience and relates an experiment where a financial executive tracked every decision he made for a year, as well as the road not taken. The full version of the interview can be watched here. A full transcript follows the video.

Audience member: Dr. Kahneman, thank you so much for visiting us at The Motley Fool. We are really pleased. We've all learned a lot from you, and we've learned even more in this hour.

When you mentioned, "The more you live, the less you feel that you know," it reminds me of a great quote from, I think it was Archbishop William Temple, who once said, "The greater the island of knowledge, the longer the coastline of mystery." I think that's a wonderful way of thinking about the progression that we all go through over the course of our lives.

I wanted to ask you simply, I see something in the financial world, because that's our world, that looks broken to me and it's probably also broken in other areas of the world, and it's that there is no scorekeeping mechanism.

If people can make predictions and no one's actually holding them accountable or scoring them, then if you think of systems thinking, it's just fundamentally broken and we can't progress. But as soon as you do start to score -- I often liken it to baseball, where everything is scored -- I wish that more for our financial world, for our political world, and others.

Do you see good score systems in the world that we should all learn from, and/or do you have any thoughts about scorekeeping? Thank you.

Daniel Kahneman: I think there is really too little scorekeeping. It's sort of astonishing when you think of those CFOs coming in year after year, and making predictions that make no sense, and they come back next year with the same level of confidence. There is no improvement. There is some absence of scorekeeping there.

On the other hand, there are really many people I think that -- most of us -- have a lot to lose from accurate scorekeeping. That's because of what I said earlier, of our ability for self-delusion, which is really a major asset in our lives. That we can lose.

I have given that advice, to keep score and when you make a decision, document the options that you considered but didn't choose. I was giving that advice a lot, and there was one place -- I didn't know it immediately -- somebody took my advice.

It was in a financial firm. I won't mention what it was. For a year, he kept track of every decision he made and the options he considered and rejected. There was a fair amount of material collected by the end of the year.

Then they told me about it, and we analyzed it. That guy was making well in excess of a million a year, and the conclusion, which I didn't share with anybody, they didn't need him. They could have saved a million dollars. He was adding nothing.

That's the kind of thing that people expose themselves to when they keep score. It's a dangerous activity.

Big Pharma's Biggest Grudge Match

They compete in the diabetes market. The same holds true for the cardiovascular, neuroscience, oncology, and osteoporosis markets. Their animal health units go head to head. You might even say that Eli Lilly (NYSE: LLY  ) and Merck (NYSE: MRK  ) are engaged in big pharma's biggest grudge match.

Which of these two rivals makes the best investing choice right now? Let's look at how Lilly and Merck stack up.

Apples to apples
There truly are plenty of areas for apples-to-apples comparisons between the two pharmaceutical companies. Merck's animal health unit stands as the larger of the two, pulling in $840 million in revenue during the first quarter versus $499 million for Lilly. Both units grew sales roughly 2% year-over-year. Lilly's animal health business comprises around 9% of total sales, while Merck's makes up nearly 8% of total sales.

Both Lilly and Merck do quite well in diabetes. Lilly's Humalog generated $633 million in sales last quarter, with Humulin garnering nearly $312 million. The company also launched Tradjenta in 2011. Lilly's U.S. patent for Humalog expires this month, but no biosimilars have yet emerged.

Merck, meanwhile, pulls in even higher sales figures. In the first quarter, diabetes drugs Januvia and Janumet racked up combined revenue of nearly $1.3 billion. While Merck's sales numbers were higher, Lilly's growth numbers looked better last quarter.

Lilly is arguably better positioned for the future in terms of products on the way. The company counts three diabetes drugs in late-stage trials plus empagliflozin in regulatory review. Merck has one diabetes drug in a late-stage study.

What about other therapeutic areas where both companies compete? Merck again outscores Lilly in cardiovascular-related revenue. Its Zetia and Vytorin combined for slightly more than $1 billion in sales last quarter. Lilly's Effient and other cardiovascular drugs brought in nearly $694 million. However, Merck's cardiovascular revenue declined slightly last quarter, while Lilly saw more than 8% sales growth for the therapeutic category.

Lilly's biggest area is neuroscience, accounting for $1.85 billion in sales for the first quarter. Merck trails behind significantly, with products like Maxalt and Remeron bringing in less than $100 million in sales during the quarter.

However, Lilly faces declining sales from Zyprexa. The company also loses patent exclusivity for Cymbalta at the end of this year. Lilly's antidepressant edivoxetine and Alzheimer's disease drug solanezumab are in late-stage trials, but neither seems likely to make up for the revenue loss from Zyprexa and Cymbalta.

Merck awaits regulatory decisions for insomnia drug suvorexant and neuromuscular blockage reversal drug sugammedex. The company has a drug targeting Parkinson's disease in a late-stage study.

Lilly claims a lead in oncology, too. Its cancer drugs, primarily Alimta and Erbitux, notched sales of $764 million during the first quarter. Merck made $332 million from Temodar and Emend. Both companies also have promising cancer drugs in late-stage studies.

In osteoporosis, Lilly again claims an advantage. Its Forteo and Evista combined for more than $522 million in sales during the first quarter. Merck's Fosamax generated sales of $137 million during the same period.

Apples to oranges
Despite several overlapping markets, Lilly and Merck focus on other areas that set the two companies apart.

Merck's respiratory products, including Singulair and Nasonex, brought in $830 million in revenue last quarter. Lilly doesn't market any comparable respiratory drugs.

Vaccines also make up a significant portion of Merck's revenue. Its vaccines, with Gardasil leading the way, generated more than $1.1 billion in the first quarter. Lilly doesn't compete in the vaccine market.

However, Lilly makes products targeting some therapeutic areas that Merck does not. For example, Lilly's Cialis, which is used to treat erectile dysfunction and benign prostatic hyperplasia, saw sales of $515 million during the first quarter. The company's attention-deficit hyperactivity disorder drug Strattera garnered nearly $167 in revenue during the period.

There's also the matter of size. Merck's market cap of nearly $140 billion doubles that of Lilly.

Grudging opinion
Who wins out in this hypothetical grudge match? I'd go with Merck.

Lilly has a huge challenge before it with several of its top drugs losing patent protection. The company counts plenty of drugs in its pipeline, but it will have a steep hill to climb in making up for lost revenue. Merck faces revenue decline related to expiring patents as well, but it shouldn't feel the brunt quite as much as Lilly.

Looking back over the last year, there's no question that Lilly's stock has performed better. However, the two companies' valuations now appear to be nearly mirror images. Lilly's trailing price-to-earnings ratio stands at 13 with a forward multiple of 20. Merck has a trailing P/E of 23 and a forward multiple of 12. Merck is much more attractively valued looking ahead.

Merck offers one more bonus. It's dividend yield of 3.7% narrowly beats the 3.5% yield of Lilly. All things considered, I think this grudge match goes to Merck.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.

Monday, July 29, 2013

Top 5 Performing Companies To Invest In Right Now

Northrop Grumman (NYSE: NOC  ) came away with more contract wins than anyone else Tuesday on the Pentagon's supplier list, scoring two contracts worth nearly $53 million, combined.

The larger of the two contracts, worth $40.5 million, tasks Northrop's Information Systems division with performing research and development, enhancement, integration, deployment and sustainment work related to the Secure Access Baseline for the EnterpRise (SABER) initiative for the Air Force Intelligence, Surveillance and Reconnaissance Agency, the Department of Homeland Security, the Defense Intelligence Agency, and other intelligence community and Department of Defense customers. Northrop has an April 9, 2018, completion date for this work.

The company also won a $12.4 million contract�to extend by four months its work on the Counter Rocket Artillery Mortar (C-RAM�) Command and Control System. C-RAM is a system that integrates the military's existing field artillery and air defense sensors with a commercial off-the-shelf warning system and a Navy-designed interceptor rocket to shoot down incoming indirect fire rounds -- mortars, artillery shells, and the like.

Top 5 Performing Companies To Invest In Right Now: Tox Free Solutions Ltd(TOX.AX)

Tox Free Solutions Limited, together with its subsidiaries, provides waste management and industrial services in Australia. The company offers chemical and hazardous waste treatment services for various materials, such as hydrocarbon contaminated soils and sludges, flammable wastes, pesticide wastes, oils and emulsions, coolants and glycols, surfactants and cleaning products, acids and alkalis, laboratory wastes, oxidizers, schedule X compounds, heavy metal bearing wastes, and spent catalysts. It also provides contaminated site remediation services, including assessment and project management; and emergency response services comprising spills and chemical cleanup, controlled and dangerous goods licensed transport, spill response and personal protective equipment, and spills kit. In addition, the company offers industrial services, such as vacuum loading; high pressure jetting, drain cleaning, and de-contamination; concrete demolition; non destructive digging; girth gear cl eaning; tank, pit, and silo cleaning; tank degassing, decommissioning, disposal, and gas free testing and certification; decontamination and clearance of hazardous waste; cleaning and descaling of cold water storage tanks and cooling towers; interceptor and plate separator cleaning and servicing; onsite oil/water separation and sludge separation; and catalyst removal and change out services to mining, oil and gas, civil infrastructure, and manufacturing industries. Further, it provides liquid waste treatment services for a range of hazardous and non hazardous bulk liquid wastes; marine and tank cleaning services consisting of cleaning of tanks, vessels, bilges, and industrial machinery, as well as liquid waste collection and waste treatment; residential, commercial, and industrial solid waste management and recycling services; and household hazardous waste collection and management services. The company was founded in 2001 and is based in West Perth, Australia.

Top 5 Performing Companies To Invest In Right Now: Health Management Associates Inc.(HMA)

Health Management Associates, Inc., through its subsidiaries, engages in the operation of general acute care hospitals and other health care facilities in non-urban communities in the United States. Its hospitals provide services, including general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, and pediatric services. The company also offers outpatient services, such as one-day surgery, laboratory, x-ray, respiratory therapy, cardiology, and physical therapy. In addition, its hospitals provide specialty services in cardiology, neuro-surgery, oncology, radiation therapy, computer-assisted tomography scanning, magnetic resonance imaging, lithotripsy, and full-service obstetrics. As of December 31, 2011, the company operated 66 hospitals with a total of 10,330 licensed beds in non-urban communities in Alabama, Arkansas, Florida, Georgia, Kentucky, Mississippi, Missouri, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Washington, and West Virginia. Health Management Associates was founded in 1977 and is based in Naples, Florida.

5 Best Warren Buffett Stocks To Own For 2014: 7 Days Group Holdings Limited(SVN)

7 Days Group Holdings Limited, through its subsidiaries, operates a chain of limited service economy hotels under the brand name of 7 Days Inn in China. The company provides accommodations and services primarily to business and leisure travelers. As of December 31, 2010, it operated 568 hotels in operation, including 247 managed hotels, with 56,410 hotel rooms in 89 cities, as well as 197 hotels with 19,345 hotel rooms under conversion. The company was founded in 2004 and is based in Guangzhou, China.

Top 5 Performing Companies To Invest In Right Now: Telik Inc (TELK.PH)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tole rated. In June 2011, the Company initiated a Phase II clini! c! al trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transf usions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolera bility of the combinations was similar to that expected! of e! ac! h drug ! alone.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60 404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multipl e, standard preclinical models of cancer. TLK6059! 6, a pote! nt! VGFR kin! ase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Top 5 Performing Companies To Invest In Right Now: AMCIL Ltd(AMH.AX)

Amcil Limited is a publicly owned investment manager. The firm primarily manages separate client focused equity portfolios for its clients. It invests in the public equity markets of Australia. The firm invests in growth and value stocks of large cap and small cap companies to create its portfolios. It invests in companies from media, technology, communications, and entertainment sectors. Amcil Limited was founded in 1996 and is based in Melbourne, Australia.

Will Kroger Put Another Acquisition in Its Shopping Cart?

Having conquered the southern mid-Atlantic region and the Carolinas with its acquisition of Harris Teeter (NYSE: HTSI  ) , will supermarket powerhouse Kroger (NYSE: KR  ) add the Northeast to its dominion, one of the few areas of the country where it doesn't have a presence?

While the grocer itself recently said it would be at least six months before it could consider making more acquisitions, a Wall Street Journal article last week suggested Kroger is on the short-list of candidates to buy up Great Atlantic & Pacific Tea Co., which recently emerged from bankruptcy and also operates the Pathmark, Food Emporium, Waldbaum's, and A&P chains. While it has a presence in Delaware and Maryland, states that Kroger is already well acquainted with, A&P, as the corporate giant is more commonly known, is heavily represented in Connecticut, New York, New Jersey, and Pennsylvania, areas that Kroger -- and Harris Teeter, for that matter -- have yet to penetrate.

It's certainly a rich market to tap. Even the ailing A&P chains had racked up almost $9 billion in sales before entering bankruptcy protection in 2010. But intense competition from mass retailers like Wal-Mart and Target, as well as the deep discounters like Dollar General and Dollar Tree that added food and other consumables to their aisles, cut into performance.  

The Northeast is also a high-cost region to operate in, particularly because of labor costs, and it was only because of concessions approved by the heavily unionized chain that A&P was able to be bought by private equity in bankruptcy rather than sold off piecemeal. Add in a series of ill-timed acquisitions such as the 2007 buyout of the Pathmark chain, which itself has been a perennial underachiever, and the addition of a boatload of debt, and A&P has not been a top-notch profit center.

The Journal puts a potential value on A&P at around $1 billion, and also names Stop & Shop parent Ahold as a potential acquirer, as well as P/E firm Cerberus Capital Management, but there are doubts any of the three would actually want A&P at the moment.

As mentioned, Kroger is still swallowing Harris Teeter and has said it needs time to make more acquisitions. Royal Ahold (NASDAQOTH: AHONY  ) is also said to be leery about doing large acquisitions these days, while Cerberus recently finished acquiring the Albertsons and Acme chains from SUPERVALU (NYSE: SVU  )  for $3.3 billion.

Of the three, however, I see Ahold as perhaps the best bet. It sold its stake in a Swedish grocery chain for $3.1 billion, but it's expanding its presence in the U.S. and likes to buy local stores to do so. That would mesh well with the image of A&P and would seem a good fit. Ahold was also thought of as a potential buyer of Harris Teeter before Kroger stepped in, so buying A&P might be a worthy complement to its Stop & Shop chain, which also has a heavy presence in the Northeast. It might allow it to keep the best of the stores going while shedding the dreck that still remains in the 300-plus-store chain.

Kroger's getting a lot of headline play out of the speculation, but I don't see it as the ultimate winner here.

The retail space is in the midst of the biggest paradigm shift since mail order took off at the turn of last century. Only those most forward-looking and capable companies will survive, and they'll handsomely reward those investors who understand the landscape. You can read about the 3 Companies Ready to Rule Retail in The Motley Fool's special report. Uncovering these top picks is free today; just click here to read more.

Ford's Pension Problem Could Improve Quickly


Ford CEO Alan Mulally has turned around the automaker through excellent management decisions. Photo credit: Ford Motor Company.

I recently wrote a brief article regarding Ford's (NYSE: F  ) underfunded pension plan and how low discount rates have played a role in creating a huge obligation for the company. At the end of 2012, with discount rates at low levels, the company left an underfunded pension plan to the tune of $18.7 billion – larger than Ford's automotive debt of $15.8 billion. What most people don't understand is how quickly this can turn around as rates rise.

Break it down
As discount rates rise, obligations decline – simple right? But that doesn't put into perspective how much or how fast this can happen. For General Motors (NYSE: GM  ) , which has a pension plan underfunded by a staggering $27.8 billion, an increase of one percentage point in the discount rate would cut $8.76 billion from its obligation value, according to Automotive News. A similar rate increase would reduce Ford's obligation by $5.2 billion – more than it has paid into the fund in the last two years combined.

In Ford's second-quarter conference call and presentation it was very clear that management is happy with how its underfunded pension plan has been progressing this year. The reason is that Ford has witnessed a 70-80 basis point rise in discount rates this year. An increase toward the high end of that range would reduce Ford's pension gap by 42%, down to $10.8 billion by the end of this year, said Matthew Stover, an auto analyst with Guggenheim Securities, according to Automotive News.

While that's very promising, that's only part of the equation. On the other side of the equation, Ford is putting more cash into the fund than it has previously. In 2011, it put in $1.1 billion, and it increased the amount to $3.4 billion last year. Both amounts still pale in comparison to the $5 billion in planned contributions this year (much of that $5 billion will consist of voluntary or excess payments).

Consider that through the first half of 2013 Ford has paid in $2.8 billion, of which $2 billion was paid voluntarily. Meanwhile, GM isn't required to make any contributions to its pension plans this year, and will make a voluntary payment of just under $1 billion – still far behind Ford in tackling the problem with voluntary payments.

In addition to adding more capital into the fund, Ford is also exercising a pension buyout strategy this year. Essentially, it's offering some retired employees a choice to take a lump sum, and it already has completed about 60% of expected settlements, according to Ford's second-quarter presentation.

While this likely won't save Ford much money, it will reduce the risk of its pension plan simply by handing out lump sums and immediately reducing the massive size of the pension plan on the books. It essentially pushes the risk onto its retired employees, who could potentially spend their lump sum retirement too quickly or be affected by other macroeconomic events that Ford will now partially avoid.

On the other hand, Ford retirees who are worried about losing pension payments due to bankruptcy or other issues can have peace of mind by securing their money ahead of time – and those in Detroit are all likely weary of bankruptcy by now. Ultimately this can be a win-win situation, and is the type of management decision we are accustomed to at Ford over the last few years.

Bottom line
Excellent management is one of many reasons I bought into Ford stock before I bought into GM in an attempt to profit from the rebounding automotive industry. Ford's underfunded pension is in much better shape than GM's, in my opinion, and will likely be resolved in 2015. That will remove one of the largest overhangs on Ford stock and also provide billions of cash flow to put into use elsewhere, such as share buybacks, increased dividend, or R&D to develop more successful vehicles.

All in all, when you buy a stock you're putting trust in management to run the company well and distribute profits – Ford's management has proven time and time again that your investment is in safe hands.

Can Ford's excellent management succeed in the one market that could bring massive profits to you? China is already the world's largest auto market -- and it's set to grow even bigger in coming years. A recent Motley Fool report, "2 Automakers to Buy for a Surging Chinese Market", names two global giants poised to reap big gains that could drive big rewards for investors. You can read this report right now for free -- just click here for instant access.

How Far Can Visa Earnings Climb?

Visa (NYSE: V  ) will release its quarterly report tomorrow, and anticipating continued strong growth, investors haven't hesitated to pile into the stock. Because of the company's position atop the credit card network industry, Visa earnings have been growing at a breakneck pace in recent years, and at least for now, that dominance appears likely to continue.

Despite its current leadership position, though, Visa's future is by no means assured in the long run. The transition from physical cards to mobile payments could pass the card giant by if it isn't careful to defend its turf and innovate along with its competitors. Can the company manage to thread the needle between keeping up with technological advances while not cannibalizing its own business? Let's take an early look at what's been happening with Visa over the past quarter and what we're likely to see in its quarterly report.

Stats on Visa

Analyst EPS Estimate

$1.80

Change From Year-Ago EPS

15.4%

Revenue Estimate

$2.89 billion

Change From Year-Ago Revenue

12.9%

Earnings Beats in Past 4 Quarters

4

Source: Yahoo! Finance.

How can Visa earnings continue to grow?
In recent months, analysts have boosted their views on Visa earnings, raising their June-quarter estimates by $0.02 per share but making bigger increases in the $0.15 to $0.25 per share range for this fiscal year and next. The stock has kept rising to record highs, with gains of more than 18% since mid-April.

The scope of Visa's business is truly astonishing. In the first quarter, Visa topped the $1.6 trillion mark in total dollar volume, staying ahead of the surging MasterCard (NYSE: MA  ) with its faster 12% dollar-volume growth rate bringing it to almost $950 billion. That keeps the pair comfortably ahead of American Express (NYSE: AXP  ) , which gets a big portion of its revenue not from payment processing but from taking on credit risk associated with actually issuing its own cards. Visa had 2.1 billion cards with its logo as of the end of 2012, beating out its rivals on that score as well.

But Visa faces two major threats. One comes from electronic payments, as eBay's (NASDAQ: EBAY  ) PayPal division has done an excellent job of boosting its volumes not just from online payments but also by tapping the rapidly growing mobile space. PayPal's success has spurred many other companies to follow suit, ranging from major tech companies like Google and Amazon to tiny upstarts like Square. Visa has taken steps to defend its traditional payment-processing territory, but even the credit card industry's joint efforts might not be enough to hold off PayPal in the long run.

The other threat comes from regulation. Earlier this month, the European Commission proposed caps on interchange fees at 0.2% for debit cards and 0.3% for credit cards. Although Visa and MasterCard have already capped their fees in Europe, the EC's move shows that the prevailing sentiment is against high card fees, and copycat regulatory moves by other countries could hamper Visa's growth prospects as it seeks to expand its global reach.

In the Visa earnings report, watch for new CEO Charles Scharf to keep elaborating on his long-term vision for Visa to go beyond its traditional card business to embrace electronic payments and other innovative methods. In the meantime, plastic isn't going away anytime soon, and as long as the global economy doesn't slow much more dramatically, worldwide opportunities should help Visa's earnings keep growing.

The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Click here to add Visa to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Sunday, July 28, 2013

Don't Get Too Worked Up Over Fabrinet's Earnings

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings' unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Fabrinet (NYSE: FN  ) , whose recent revenue and earnings are plotted below.

Source: S&P Capital IQ. Data is current as of last fully reported fiscal quarter. Dollar values in millions. FCF = free cash flow. FY = fiscal year. TTM = trailing 12 months.

Over the past 12 months, Fabrinet generated $35.6 million cash while it booked net income of $61.3 million. That means it turned 5.7% of its revenue into FCF. That sounds OK. However, FCF is less than net income. Ideally, we'd like to see the opposite.

All cash is not equal
Unfortunately, the cash flow statement isn't immune from nonsense, either. That's why it pays to take a close look at the components of cash flow from operations, to make sure that the cash flows are of high quality. What does that mean? To me, it means they need to be real and replicable in the upcoming quarters, rather than being offset by continual cash outflows that don't appear on the income statement (such as major capital expenditures).

For instance, cash flow based on cash net income and adjustments for non-cash income-statement expenses (like depreciation) is generally favorable. An increase in cash flow based on stiffing your suppliers (by increasing accounts payable for the short term) or shortchanging Uncle Sam on taxes will come back to bite investors later. The same goes for decreasing accounts receivable; this is good to see, but it's ordinary in recessionary times, and you can only increase collections so much. Finally, adding stock-based compensation expense back to cash flows is questionable when a company hands out a lot of equity to employees and uses cash in later periods to buy back those shares.

So how does the cash flow at Fabrinet look? Take a peek at the chart below, which flags questionable cash flow sources with a red bar.

Source: S&P Capital IQ. Data is current as of last fully reported fiscal quarter. Dollar values in millions. TTM = trailing 12 months.

When I say "questionable cash flow sources," I mean items such as changes in taxes payable, tax benefits from stock options, and asset sales, among others. That's not to say that companies booking these as sources of cash flow are weak, or are engaging in any sort of wrongdoing, or that everything that comes up questionable in my graph is automatically bad news. But whenever a company is getting more than, say, 10% of its cash from operations from these dubious sources, investors ought to make sure to refer to the filings and dig in.

With questionable cash flows amounting to only -0.4% of operating cash flow, Fabrinet's cash flows look clean. Within the questionable cash flow figure plotted in the TTM period above, stock-based compensation and related tax benefits provided the biggest boost, at 8.8% of cash flow from operations. Overall, the biggest drag on FCF came from capital expenditures, which consumed 33.3% of cash from operations.

A Foolish final thought
Most investors don't keep tabs on their companies' cash flow. I think that's a mistake. If you take the time to read past the headlines and crack a filing now and then, you're in a much better position to spot potential trouble early. Better yet, you'll improve your odds of finding the underappreciated home-run stocks that provide the market's best returns.

If you're interested in companies like Fabrinet, you might want to check out the jaw-dropping technology that's about to put 100 million Chinese factory workers out on the street – and the 3 companies that control it. We'll tell you all about them in "The Future is Made in America." Click here for instant access to this free report.

We can help you keep tabs on your companies with My Watchlist, our free, personalized stock tracking service.

Add Fabrinet to My Watchlist.

Does Pandora Need a Partner?

While Pandora (NYSE: P  ) has long been a leader in Internet radio, the release of iTunes Radio from Apple (NASDAQ: AAPL  ) poses a serious threat. Not only given Apple's might in hardware, but considering that Cupertino is taking a hard-charging approach to getting inside your car -- a critical area for Pandora -- it may be time for the media company to look at its options beyond pure head-to-head competition.

In the following video, Fool.com contributor Doug Ehrman discusses the radio industry, why attracting listeners in their cars is such a critical area, and one way in which Pandora might look to the future as the competition with Apple and others intensifies.

Just as the battle for your radio is well under way, the future of television is at stake in an all-out $2.2 trillion media war that pits the cable companies against the technology giants. The Motley Fool's shocking video presentation reveals the secret Steve Jobs took to his grave and explains why the only real winners are these three lesser-known power players that film your favorite shows. Click here to watch today!

The iPhone Is Creating a Photography Boom

5 of Last Week's Biggest Losers

Top 10 Medical Companies To Own For 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Natus Medical (NASDAQ: BABY  ) , a neurodiagnostic and medical device company specializing in newborn and infant care, sank as much as 15% after the company announced disappointing preliminary revenue figures for the second quarter.

So what: Shareholders were certainly reaching for their safety blanket after waking up this morning to updated revenue guidance from Natus calling for $81 million to $82 million in sales compared to its own previous guidance of $86 million to $90 million ��and well below the Street's forecast of $88.8 million. Natus noted that U.S. sales remain on track to hit their targets, but a rapid drop-off in international sales, specifically in Europe, led to the shortfall.

Top 10 Medical Companies To Own For 2014: Prima BioMed Ltd (PRR)

Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates.

Top 10 Medical Companies To Own For 2014: Terumo (TRUMY.PK)

TERUMO CORPORATION operates in four business segment. The Hospital Products segment is engaged in the manufacture, purchase and sale of hospital medical equipment, pharmaceuticals, peritoneal dialysis and diabetes related products, and the rental of hospital medical equipment and home medical products. The Cardiac and Vascular Area segment is involved in the manufacture, purchase and sale of catheter systems, artificial heart and lungs, as well as artificial blood vessels, the manufacture and sale of therapeutic coils for cerebral aneurysm, sampling equipment and kits for platelet-rich plasma and concentrated bone-marrow cell, and large-bore sheaths. The Blood System segment is engaged in the manufacture, purchase and sale of blood transfusion-related products. The Healthcare segment manufactures and sells healthcare related products. As of March 31, 2012, the Company had 79 subsidiaries and 2 associated companies. Advisors' Opinion:
  • [By Robert Holmes]

     Analyst Mayo Mita says the Japanese earthquake and tsunami was a setback for the company, Terumo has a more visible growth stage coming.

    "Over the next five years we see clear growth from China, the NOBORI drug eluting stent (DES), the U.S. catheter business, and the blood management business," Mita writes.

    The base-case Mita lays out is for a 26% rise in share price next year, although Mita's most bullish forecast has shares up twice that. On the downside, Mita's most bearish scenario has shares falling 11% in the next 12 months.

    The chart below shows shares of Terumo that trade on the Pink Sheets in the U.S., but Morgan Stanley is recommending buying shares in Tokyo.

10 Best Stocks To Buy Right Now: Bio-Reference Laboratories Inc.(BRLI)

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.

Advisors' Opinion:
  • [By Squeeze Ideas]

    Medical Laboratories & Research Industry. Market cap of $621.05M. Short float at 24.02% (equivalent to 25.29 days of average volume).

    Net Income grew by 19.5% ($8.58M vs. $7.18M y/y), while Operating Cash Flow grew by 21.38% ($9.88M vs. $8.14M y/y) (comparing 3 months ending 2010-10-31 vs. 3 months ending 2009-10-31).

    The stock has a relatively low correlation to the market (beta = 0.71), which may be appealing to risk averse investors.

    Other Highlights: Judging by trailing twelve month (TTM) ratios like Return on Equity (ROE), Return on Assets (ROA) and Return on Invested Capital (ROI), it's clear that the company's management is doing an excellent job. TTM ROE at 20.49%, higher than the industry average at 17.9%, TTM ROA at 12.68% vs. the industry average at 6.71%, and TTM ROI at 16.16%, higher than the industry average at 11.34%. The company also outperformed its industry competitors in terms of the TTM Return on Sales ratio (6.32% vs. the industry average at 4.52%).

Top 10 Medical Companies To Own For 2014: CEL-SCI Corp (CVM)

CEL-SCI Corporation (CEL-SCI), incorporated on March 22, 1983, is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.

Multikine

CEL-SCI's Multikine, is being developed for the treatment of cancer. It is a cancer immunotherapy drugs called Combination Immunotherapy because it combines active and passive immunity in one product. It is the only cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer. Multikine target the tumor micro-metastases for treatment failure. Multikine is also applicable in many other solid tumors.

New Manufacturing Facility

CEL-SCI's facility manufactures Multikine for CEL-SCI's Phase III clinical trial. CEL-SCI offers the use of the facility as a service to pharmaceutical companies and others, particularly those that need to fill and finish their drugs in a cold environment. Fill and finish is the process of filling injectable drugs in a sterile manner.

LEAPS

CEL-SCI's patented T-cell Modulation Process uses heteroconjugates to direct the body to choose a specific immune response. The heteroconjugate technology, referred to as LEAPS, is intended to stimulate the human immune system to fight bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer. Administered like vaccines, LEAPS combines T-cell binding ligands with small, disease associated and peptide antigens.

Using the LEAPS technology, CEL-SCI has created a peptide treatment for H1N1 (swine flu) hospitalized patients. This LEAPS flu treatment is designed to focus on the conserved, non-changing epitopes of the di! fferent strains of Type A Influenza viruses, including swine, avian or bird, and Spanish Influenza. CEL-SCI's LEAPS flu treatment contains epitopes.

Top 10 Medical Companies To Own For 2014: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Top 10 Medical Companies To Own For 2014: Algeta ASA (ALGETA.OL)

Algeta ASA is a Norway-based biotechnology company engaged in the development of targeted cancer therapies based on its alpha-pharmaceutical platform. The Company�� principal product is Alpharadin for the treatment of bone metastases resulting from castration-resistant prostate cancer. The Company�� pipeline also includes Alpharadin for the treatment of bone metastases resulting from breast cancer, a combination of Alpharadin with Taxotere for the treatment of bone metastases resulting from prostate cancer and Thorium-227 showing various cancer indications. The Company develops Alpharadin in a development and marketing cooperation with Bayer Schering Pharma. Algeta ASA is active through the two wholly owned subsidiaries, Algeta Innovations AS and Algeta UK Limited. On April 12, 2012, the Company announced that it estabilished a subsidiary active in the United States, Algeta US.

Top 10 Medical Companies To Own For 2014: Covidien PLC (COV)

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, SharpSafety products and original equipment manufacturer products. In May 2012, it acquired Newport Medical Instruments, Inc. In May 2012, it acquired superDimension, Ltd. In June 2012, the Company acquired Oridion Systems Ltd. In October 2012, its Mallinckrodt acquired CNS Therapeutics, Inc. In January 2013, the Company acquired CV Ingenuity. Advisors' Opinion:
  • [By James K. Glassman]

    A global leader in medical devices, supplies and drugs, Covidien (symbol: COV) isn’t resting easy. The company, based in Ireland, expects to launch 100 new products through 2014. And it will continue to increase its research-and-development budget at a double-digit pace. Another goal: capitalize on emerging markets, where annual sales are growing rapidly. Analysts see Covidien’s plan to spin off its drug business as a positive, allowing the company to focus on its faster-growing and more-profitable devices business. The stock sells for 13 times estimated 2013 profits and yields 1.8%.

  • [By James K. Glassman]

     A global leader in medical devices, supplies and drugs, Covidien (symbol: COV) isn’t resting easy. The company, based in Ireland, expects to launch 100 new products through 2014. And it will continue to increase its research-and-development budget at a double-digit pace. Another goal: capitalize on emerging markets, where annual sales are growing rapidly. Analysts see Covidien’s plan to spin off its drug business as a positive, allowing the company to focus on its faster-growing and more-profitable devices business. The stock sells for 13 times estimated 2013 profits and yields 1.8%.

  • [By Roberto Pedone]

    Covidien (COV) has a market capitalization of $29.74 billion. The company employs 43,400 people, generates revenue of $11.852 billion and has a net income of $1.902 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $3.044 billion. The EBITDA margin is 25.68 percent (the operating margin is 20.34 percent and the net profit margin 16.05 percent). 

    Financial Analysis: The total debt represents 22.64 percent of the company’s assets and the total debt in relation to the equity amounts to 47.70 percent. Due to the financial situation, a return on equity of 18.66 percent was realized. Twelve trailing months earnings per share reached a value of $3.93. Last fiscal year, the company paid $0.94 in the form of dividends to shareholders. 

    Market Valuation: Here are the price ratios of the company: The P/E ratio is 15.97, the P/S ratio is 2.52 and the P/B ratio is finally 2.83. The dividend yield amounts to 1.64 percent and the beta ratio has a value of 0.89.

Top 10 Medical Companies To Own For 2014: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.

Advisors' Opinion:
  • [By Michael Brush]

    Johnson & Johnson has a dividend yield of 3.4%.

    The world's largest health care company provides investors with exposure (similar to that of a mutual fund) to the health care sector. The company has three main divisions: pharmaceuticals, medical devices and consumer products.

    Johnson & Johnson has had its share of quality control issues, but that's no reason to avoid this stock. The company's strong research pipeline, broad product lines and abundant cash flow mean it will continue to grow -- and keep increasing dividends.

Top 10 Medical Companies To Own For 2014: Telik Inc (TELK.PH)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tole rated. In June 2011, the Company initiated a Phase II clini! c! al trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transf usions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolera bility of the combinations was similar to that expected! of e! ac! h drug ! alone.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60 404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multipl e, standard preclinical models of cancer. TLK6059! 6, a pote! nt! VGFR kin! ase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Top 10 Medical Companies To Own For 2014: DENTSPLY International Inc.(XRAY)

DENTSPLY International Inc. designs, develops, manufactures, and markets dental consumable products, dental laboratory products, and dental specialty products worldwide. The company?s dental consumable products include dental sundries, such as dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride; and small equipment, including high and low speed handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers used in dental offices for the treatment of patients. Its dental laboratory products comprise dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials, as well as equipment, such as computer aided machining ceramic systems and porcelain furnaces used in the preparation of dental appliances by dental laboratories. The company?s dental specialty products consist of endodonti c instruments and materials, implants and related products, bone grafting materials, 3D digital implantology, and orthodontic appliances and accessories. Its customers include dentists, dental hygienists, dental assistants, dental laboratories, and dental schools. The company distributes its dental products directly to dental laboratories and dental professionals, as well as through distributors, dealers, and importers. DENTSPLY International Inc. was founded in 1983 and is headquartered in York, Pennsylvania.

Advisors' Opinion:
  • [By Newsy Stocks]

    DENTSPLY International Inc. (Nasdaq: XRAY) designs, develops, manufactures, and markets dental consumable products, dental laboratory products, and dental specialty products worldwide. The company has a total market capitalization of $4.8 billion and in the last 1-year the stock has given a return of 11.8 percent. The company has a dividend yield of 0.59 percent, and has a price of profit of 16. The stock is trading at a P/E of 17.46, higher than the industry’s average P/E of 15.81. The PEG ratio of the stock is 1.65 years, higher than industry’s PEG of 1.15 years. The average 5 years historical earnings growth is 7.50 percent and is expected to grow at 11.20 percent for the next 5 years. Its quarterly revenue growth is estimated at 6.83 percent. The stock has a P/B value of 2.30x percent. Analyst at Barrington Research has given it an outperform rating on $42.75 price target. Based on the price target the stock is trading at a dis count of 21.73 percent. XRAY was up 1.98 percent to $34.01 a share.